Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Life Biosciences Inc.
Headquarters: Boston, MA, United States of America
Website: https://lifebiosciences.com
Year Founded: 2017
Status: Private
BioCentury | Jan 28, 2025
Management Tracks
Thomas Barnes named CEO of Averna
Plus: Panetta given emeritus title at Biocom and updates from Kailera, Harness, Nuevocor, Janux, Umoja and more
BioCentury | May 23, 2023
Management Tracks
Obsidian fills CEO, CDO roles with Iovance vets
Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more
BioCentury | Feb 14, 2023
Management Tracks
J&J hires Sanofi’s Reed
Plus: Roth named COO at Zentalis and updates from Treeline, SpyBiotech and Life
BioCentury | Dec 24, 2022
BioCentury Commentary
Noisemakers and newsmakers of 2022, and hot takes for 2023
BioCentury’s analysts look back at a year when industry took some slings and arrows but delivered breakthroughs, and predict what’ll be hot in 2023
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Jan 7, 2022
Deals
Jan. 6 Quick Takes: Nextech leads $85M A round for molecular glue newco Ambagon
Plus: Odyssey builds out tool kit and updates from Amgen-Generate, Verily-Sosei, TRexBio-Janssen, Sutro, Sanofi and more
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Jun 5, 2021
Distillery Therapeutics
Small molecule activator of chaperone-mediated autophagy for Alzheimer’s
DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease A phenylacetamide-based compound that activates chaperone-mediated autophagy could treat Alzheimer’s disease. An expression
INDICATION: Alzheimer’s disease A phenylacetamide-based compound that activates chaperone-mediated autophagy could treat Alzheimer’s disease. An expression
BioCentury | Feb 3, 2021
Management Tracks
Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital
China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that
Items per page:
1 - 10 of 15